Friedlander, Michael

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 2,954

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,870

Genome-wide association study identifies novel breast cancer susceptibility loci

Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature

Genetic Associations and EpidemiologyBRCA gene mutations in cancer

Cited by 2,319

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,279

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 1,655

The importance of patient-reported outcomes in clinical trials and strategies for future optimization

Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M. (2018) · Patient Related Outcome Measures

Statistical Methods in Clinical TrialsHealth Systems, Economic Evaluations, Quality of Life

Cited by 659

Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial

DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 511

“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer Treatments

Cited by 433

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Phillips, K.-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., et al. (2013) · Journal of Clinical Oncology

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 171

Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study

Goldstein, D., Bennett, B. K., Webber, K., Boyle, F., de Souza, P. L., Wilcken, N. R. C., Scott, E. M., Toppler, R., Murie, P., O'Malley, L., et al. (2012) · Journal of Clinical Oncology

Cancer survivorship and careCancer-related cognitive impairment studies

Cited by 140

Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs

Butow, P. N., The Australian Ovarian Cancer Study Group, Price, M. A., Bell, M. L., Webb, P. M., deFazio, A., The Australian Ovarian Cancer Study Quality of Life Study Investigators, & Friedlander, M. (2014) · Gynecologic Oncology

Palliative Care and End-of-Life IssuesCancer survivorship and care

Cited by 119

Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor

Price, M. A., Zachariae, R., Butow, P. N., deFazio, A., Chauhan, D., Espie, C. A., Friedlander, M., & Webb, P. M. (2009) · European Journal of Cancer

Sleep and related disordersCancer survivorship and care

Cited by 56

Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study

Sjoquist, K. M., Friedlander, M. L., O'Connell, R. L., Voysey, M., King, M. T., Stockler, M. R., Oza, A. M., Gillies, K., Martyn, J. K., & Butow, P. N. (2013) · The Oncologist

Optimism, Hope, and Well-beingCancer survivorship and care

Cited by 43

Molecular and Clinical Predictors of Improvement in Progression‐free Survival with Maintenance PARP Inhibitor Therapy in Women with Platinum‐sensitive, Recurrent Ovarian Cancer: A Meta‐analysis

Lee, C. K., Friedlander, M. L., Tjokrowidjaja, A., Ledermann, J. A., Coleman, R. L., Mirza, M. R., Matulonis, U. A., Pujade‐Lauraine, E., Bloomfield, R., Goble, S., et al. (2021) · Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 36

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 32